Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANALYSIS: What Would A Teva-Mylan Deal Mean For India?

This article was originally published in PharmAsia News

Executive Summary

The situation is still fluid on a possible merger between Teva and Mylan and will likely see a few quick and dramatic turns over the next few weeks. In the event a deal does click, it would have a significant impact on the two firms’ Indian businesses and also Indian generic manufacturers more generally.

You may also be interested in...



Two Roads Diverge For Mylan: Teva Or Perrigo

Teva announced a proposal to acquire Mylan for $82 per share, or roughly $40 billion, putting Mylan’s independence and a proposal to acquire OTC drug specialist Perrigo in question. Adding to the uncertainty, Perrigo rejected Mylan’s offer after market close.

Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move

Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.

Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on

MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC088811

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel